Gilead Sciences: Underestimated Biotech Giant with Surprising Growth Potential

Gilead Sciences' Q4 earnings are expected to show significant momentum in its HIV franchise, with total revenue rising 3% YoY to $7.8 billion. The company's HIV product sales grew 4% YoY to $5.3 billion, driven by strong demand for Biktarvy and Descovy. The PrEP market expanded at a rate of 14%-15% YoY, expected to sustain through 2026. The liver disease portfolio also had a strong quarter, with sales up 12% YoY to $819 million.